Deven Parmar

Trials

Studies that name Deven Parmar as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 03:49 UTC. Open this list on ClinicalTrials.gov

• Ph1
  NCT06825559 · Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease

  Zydus Therapeutics Inc. · recruiting · Cholestatic Liver Disease · study director
• Ph3
  NCT06427395 · Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis

  Zydus Therapeutics Inc. · active not recruiting · Primary Biliary Cholangitis · study director
• Ph2
  NCT06398808 · A Study to Evaluate the Efficacy and Safety of ZYIL1 Oral Capsules for the Treatment of Patients With Mild to Moderately Active Ulcerative Colitis Resistant or Intolerant to Oral Aminosalicylates

  Zydus Lifesciences Limited · completed · Ulcerative Colitis · study chair
• Ph2
  NCT05981040 · Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZYIL1 in Patients With Amyotrophic Lateral Sclerosis

  Zydus Lifesciences Limited · completed · Amyotrophic Lateral Sclerosis · study chair
• Ph1
  NCT05911828 · A Study to Determine Safety, Tolerability, and Pharmacokinetics of Different Orally Administered Regimens of the Combination ZY19489-Ferroquine in Adult Asymptomatic Plasmodium Falciparum Carriers

  Zydus Lifesciences Limited · unknown · Uncomplicated Malaria, Asymptomatic Condition, Falciparum Malaria · study director
• Ph4
  NCT05872269 · A Study to Evaluate the Safety and Effectiveness of Saroglitazar 4 mg in Patients With NAFLD With Comorbidities

  Zydus Lifesciences Limited · unknown · NAFLD, Obesity, Type 2 Diabetes · study chair
• Ph4
  NCT05515367 · A Post Marketing Surveillance to Evaluate the Safety of Desidustat for the Treatment of Anemia in Subjects With Chronic Kidney Disease (CKD).(Real World Evidence Study)

  Zydus Lifesciences Limited · recruiting · Chronic Kidney Diseases, Anemia of Chronic Kidney Disease · study chair
• Ph3
  NCT05283837 · A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,)

  Zydus Lifesciences Limited · completed · Metastatic Breast Cancer · study director
• Ph1
  NCT05206201 · A Study Of Zy-19489 Administered Via Oral Route To Investigate The Safety, Tolerability And Pharmacokinetics In Healthy Adult Human Subjects

  Zydus Lifesciences Limited · completed · Malaria · study chair
• Ph2
  NCT05186051 · A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZYIL1 in Subjects With Cryopyrin Associated Periodic Syndromes (CAPS)

  Zydus Lifesciences Limited · completed · Cryopyrin Associated Periodic Syndrome · study director
• Ph1
  NCT04972188 · A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of ZYIL1 Following Oral Administration in Healthy Volunteers

  Zydus Lifesciences Limited · completed · Healthy · study chair
• Ph1
  NCT04731324 · Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of ZYIL1 Following Oral Administration in Healthy Volunteers

  Zydus Lifesciences Limited · completed · Healthy · study chair
• Ph1
  NCT04667533 · Desidustat in the Treatment of Chemotherapy Induced Anemia

  Zydus Lifesciences Limited · completed · Anemia of Chronic Kidney Disease, Chemotherapy Effect · study chair
• Ph2
  NCT04480138 · Pegylated Interferon - α2b With SARSCoV- 2 (COVID-19)

  Zydus Lifesciences Limited · terminated · Covid19 · study director
• Ph1
  NCT04469920 · Hepatic Impairment, Cholestatic Liver Disease, & NASH with Advanced Fibrosis & Normal Hepatic Function

  Zydus Therapeutics Inc. · completed · Hepatic Impairment · study director
• Ph2
  NCT04463602 · Desidustat in the Management of COVID-19 Patients

  Zydus Lifesciences Limited · completed · COVID-19 · study director
• Ph1
  NCT04446507 · A Pharmacokinetic Study of Saroglitazar Magnesium in Subjects with Severe Renal Impairment and Normal Renal Function

  Zydus Therapeutics Inc. · completed · Renal Impairment · study director
• Ph3
  NCT04215120 · Desidustat in the Treatment of Anemia in CKD on Dialysis Patients

  Zydus Lifesciences Limited · completed · Chronic Kidney Disease Stage 5 on Dialysis · study director
• Ph2
  NCT03639623 · Safety, Tolerability, and Efficacy of Saroglitazar Mg 4 mg in Liver Transplant Recipients With Nonalcoholic Fatty Liver Disease (NAFLD)

  Zydus Therapeutics Inc. · completed · Liver Transplant; Complications, NAFLD · study director
• Ph2
  NCT03617263 · Saroglitazar Magnesium 4 mg in the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Women With PCOS (EVIDENCES VII)

  Zydus Therapeutics Inc. · terminated · Non-alcoholic Fatty Liver Disease in Women With PCOS · study director
• Ph2
  NCT03112681 · Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Mg in Patients With Primary Biliary Cholangitis

  Zydus Therapeutics Inc. · completed · Primary Biliary Cirrhosis · study director

Grants

NIH projects from RePORTER, fetched 2026-11-12 03:49 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.